BioArctic AB
STO:BIOA B

Watchlist Manager
BioArctic AB Logo
BioArctic AB
STO:BIOA B
Watchlist
Price: 142.3 SEK -1.52% Market Closed
Market Cap: 12.6B SEK
Have any thoughts about
BioArctic AB?
Write Note

Intrinsic Value

The intrinsic value of one BIOA B stock under the Base Case scenario is 179.45 SEK. Compared to the current market price of 142.3 SEK, BioArctic AB is Undervalued by 21%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BIOA B Intrinsic Value
179.45 SEK
Undervaluation 21%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BioArctic AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BIOA B cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BIOA B?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about BioArctic AB

Provide an overview of the primary business activities
of BioArctic AB.

What unique competitive advantages
does BioArctic AB hold over its rivals?

What risks and challenges
does BioArctic AB face in the near future?

Has there been any significant insider trading activity
in BioArctic AB recently?

Summarize the latest earnings call
of BioArctic AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BioArctic AB.

Provide P/S
for BioArctic AB.

Provide P/E
for BioArctic AB.

Provide P/OCF
for BioArctic AB.

Provide P/FCFE
for BioArctic AB.

Provide P/B
for BioArctic AB.

Provide EV/S
for BioArctic AB.

Provide EV/GP
for BioArctic AB.

Provide EV/EBITDA
for BioArctic AB.

Provide EV/EBIT
for BioArctic AB.

Provide EV/OCF
for BioArctic AB.

Provide EV/FCFF
for BioArctic AB.

Provide EV/IC
for BioArctic AB.

Show me price targets
for BioArctic AB made by professional analysts.

What are the Revenue projections
for BioArctic AB?

How accurate were the past Revenue estimates
for BioArctic AB?

What are the Net Income projections
for BioArctic AB?

How accurate were the past Net Income estimates
for BioArctic AB?

What are the EPS projections
for BioArctic AB?

How accurate were the past EPS estimates
for BioArctic AB?

What are the EBIT projections
for BioArctic AB?

How accurate were the past EBIT estimates
for BioArctic AB?

Compare the revenue forecasts
for BioArctic AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BioArctic AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BioArctic AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of BioArctic AB compared to its peers.

Compare the P/E ratios
of BioArctic AB against its peers.

Discuss the investment returns and shareholder value creation
comparing BioArctic AB with its peers.

Analyze the financial leverage
of BioArctic AB compared to its main competitors.

Show all profitability ratios
for BioArctic AB.

Provide ROE
for BioArctic AB.

Provide ROA
for BioArctic AB.

Provide ROIC
for BioArctic AB.

Provide ROCE
for BioArctic AB.

Provide Gross Margin
for BioArctic AB.

Provide Operating Margin
for BioArctic AB.

Provide Net Margin
for BioArctic AB.

Provide FCF Margin
for BioArctic AB.

Show all solvency ratios
for BioArctic AB.

Provide D/E Ratio
for BioArctic AB.

Provide D/A Ratio
for BioArctic AB.

Provide Interest Coverage Ratio
for BioArctic AB.

Provide Altman Z-Score Ratio
for BioArctic AB.

Provide Quick Ratio
for BioArctic AB.

Provide Current Ratio
for BioArctic AB.

Provide Cash Ratio
for BioArctic AB.

What is the historical Revenue growth
over the last 5 years for BioArctic AB?

What is the historical Net Income growth
over the last 5 years for BioArctic AB?

What is the current Free Cash Flow
of BioArctic AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for BioArctic AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BioArctic AB

Current Assets 1B
Cash & Short-Term Investments 489.7m
Other Current Assets 540.1m
Non-Current Assets 102.2m
Long-Term Investments 3.4m
PP&E 98.1m
Other Non-Current Assets 678k
Current Liabilities 143.5m
Other Current Liabilities 143.5m
Non-Current Liabilities 59.1m
Long-Term Debt 46.8m
Other Non-Current Liabilities 12.4m
Efficiency

Earnings Waterfall
BioArctic AB

Revenue
299.3m SEK
Cost of Revenue
-35.3m SEK
Gross Profit
264.1m SEK
Operating Expenses
-360.1m SEK
Operating Income
-96m SEK
Other Expenses
7.7m SEK
Net Income
-88.3m SEK

Free Cash Flow Analysis
BioArctic AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

BioArctic reported significant growth in Leqembi sales, particularly in the U.S. and Japan, with a strong launch in China. Leqembi is now approved in eight markets, representing over 80% of the expected global demand. The company anticipates a fivefold revenue increase, projecting sales to reach $2 billion by 2026. Net revenue for the quarter was SEK 50 million, with royalties projected to average SEK 120 million quarterly over the next year. Despite a negative EU decision, BioArctic is optimistic about a favorable reexamination and expects to be profitable next year. The company is advancing its portfolio, including a Phase IIa study for exidavnemab in Parkinson's disease.

What is Earnings Call?
Fundamental Scores

BIOA B Profitability Score
Profitability Due Diligence

BioArctic AB's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
40/100
Profitability
Score

BioArctic AB's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

BIOA B Solvency Score
Solvency Due Diligence

BioArctic AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

BioArctic AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BIOA B Price Targets Summary
BioArctic AB

There are no price targets for BIOA B.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BIOA B?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BIOA B is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BIOA B Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

BioArctic AB Logo
BioArctic AB

Country

Sweden

Industry

Biotechnology

Market Cap

12.6B SEK

Dividend Yield

0%

Description

BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. The company is headquartered in Stockholm, Stockholm and currently employs 49 full-time employees. The company went IPO on 2017-10-12. The firm focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The firm owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The firm's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The firm also operates through SpineMedical AB.

Contact

STOCKHOLM
Stockholm
Warfvinges vag 35
+4686956930.0
www.bioarctic.se

IPO

2017-10-12

Employees

49

Officers

President & CEO
Dr. Gunilla Osswald Ph.D.
Co-Founder, Senior VP of Business Strategy & Director
Dr. Pär Gellerfors
Co-Founder, Senior VP of Medical science & Director
Prof. Lars Lannfelt
Chief Financial Officer
Mr. Anders Martin-Lof M.B.A., M.Sc.
Chief Research Officer & Head of Research
Ms. Johanna Fälting
VP of Pre-Clinical Development & Chief Scientific Officer
Mr. Christer Möller
Show More
VP and Head of IR & Communication
Mr. Oskar Bosson
General Counsel and Head of Legal & IP
Mr. Leif Gallo LL.M.
Head of Public Affairs
Mr. Harald Borgeke
Head of Marketing
Ms. Frida Lekander
Show Less

See Also

Discover More
What is the Intrinsic Value of one BIOA B stock?

The intrinsic value of one BIOA B stock under the Base Case scenario is 179.45 SEK.

Is BIOA B stock undervalued or overvalued?

Compared to the current market price of 142.3 SEK, BioArctic AB is Undervalued by 21%.

Back to Top